112 related articles for article (PubMed ID: 37094793)
1. [TTF-1-negative lung adenocarcinoma: special features of systemic treatment].
Frost N; Reck M
Pneumologie; 2023 Jul; 77(7):426-429. PubMed ID: 37094793
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis.
Frost N; Zhamurashvili T; von Laffert M; Klauschen F; Ruwwe-Glösenkamp C; Raspe M; Brunn M; Ochsenreither S; Temmesfeld-Wollbrück B; Suttorp N; Grohé C; Witzenrath M
Clin Lung Cancer; 2020 Nov; 21(6):e607-e621. PubMed ID: 32620471
[TBL] [Abstract][Full Text] [Related]
3. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K
Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407
[TBL] [Abstract][Full Text] [Related]
4. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Su KY; Chang YL; Wu CT; Hsu CC; Liao BC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
Eur J Cancer; 2020 Jan; 124():110-122. PubMed ID: 31760310
[TBL] [Abstract][Full Text] [Related]
5. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
[No Abstract] [Full Text] [Related]
6. Programmed death-ligand 1 (PD-L1)/thyroid transcription factor-1 double immunohistochemical staining facilitates scoring of tumor PD-L1 expression in cytopathology specimens from lung adenocarcinoma patients.
Lin YY; Lin LY; Hang JF; Lin CH; Ho HL; Chou TY
Cancer Cytopathol; 2021 Feb; 129(2):148-155. PubMed ID: 32976705
[TBL] [Abstract][Full Text] [Related]
7. Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.
Ho KH; Chang CJ; Huang TW; Shih CM; Liu AJ; Chen PH; Cheng KT; Chen KC
PLoS One; 2018; 13(12):e0208459. PubMed ID: 30521597
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.
Schoenfeld AJ; Rizvi H; Bandlamudi C; Sauter JL; Travis WD; Rekhtman N; Plodkowski AJ; Perez-Johnston R; Sawan P; Beras A; Egger JV; Ladanyi M; Arbour KC; Rudin CM; Riely GJ; Taylor BS; Donoghue MTA; Hellmann MD
Ann Oncol; 2020 May; 31(5):599-608. PubMed ID: 32178965
[TBL] [Abstract][Full Text] [Related]
9. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Liu YN; Su KY; Chang YL; Wu CT; Liao BC; Hsu CC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
Oncologist; 2020 Aug; 25(8):702-711. PubMed ID: 32386255
[TBL] [Abstract][Full Text] [Related]
10. Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma.
Nakahama K; Kaneda H; Osawa M; Izumi M; Yoshimoto N; Sugimoto A; Nagamine H; Ogawa K; Matsumoto Y; Sawa K; Tani Y; Mitsuoka S; Watanabe T; Asai K; Kawaguchi T
Thorac Cancer; 2022 Aug; 13(16):2309-2317. PubMed ID: 35808895
[TBL] [Abstract][Full Text] [Related]
11. Successful management of lung adenocarcinoma with ALK/EGFR co-alterations and PD-L1 over-expression by bevacizumab combined with chemotherapy.
He H; Yang W; Huang Y; Zhang X; Peng Y; Yang Z
Angiogenesis; 2022 Feb; 25(1):5-8. PubMed ID: 34342748
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
[TBL] [Abstract][Full Text] [Related]
13. Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies.
Nishii K; Hotta K; Ninomiya K; Kato Y; Ichihara E; Ohashi K; Ninomiya T; Kubo T; Rai K; Tabata M; Maeda Y; Kiura K
Respir Investig; 2019 Sep; 57(5):460-465. PubMed ID: 31186170
[TBL] [Abstract][Full Text] [Related]
14. A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages.
Watanabe H; Ohashi K; Nishii K; Seike K; Makimoto G; Hotta K; Maeda Y; Kiura K
Intern Med; 2019 Oct; 58(20):3033-3037. PubMed ID: 31292383
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the programmed death-ligand 1 mRNA expression and immunopositivity and their correlation with survival outcomes in Indian lung cancer patients.
Kumar S; Pandey M; Mir IA; Mukhopadhyay A; Sharawat SK; Jain D; Saikia J; Malik PS; Kumar S; Mohan A
Hum Cell; 2022 Jan; 35(1):286-298. PubMed ID: 34786661
[TBL] [Abstract][Full Text] [Related]
16. Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
Toral KJ; Wuenschel MA; Black EP
PLoS One; 2021; 16(8):e0256416. PubMed ID: 34437586
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.
Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Shimokawa M; Suzuki K
Lung Cancer; 2022 Jun; 168():50-58. PubMed ID: 35489160
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure.
Lu Z; Ye M; Sun T; Wu S; Lin Z; Zhang X; Rao D; Zhang D; Ke Y; Chen Z
Ann Palliat Med; 2022 Jun; 11(6):2100-2109. PubMed ID: 35817745
[TBL] [Abstract][Full Text] [Related]
19. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
Shinchi Y; Komohara Y; Yonemitsu K; Sato K; Ohnishi K; Saito Y; Fujiwara Y; Mori T; Shiraishi K; Ikeda K; Suzuki M
Cancer Sci; 2019 Sep; 110(9):2711-2721. PubMed ID: 31294893
[TBL] [Abstract][Full Text] [Related]
20. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Han K; Zhang Y
J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
